Navitoclax
CAS No. 923564-51-6
Navitoclax ( ABT-263;ABT 263;ABT263 )
Catalog No. M16614 CAS No. 923564-51-6
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 37 | In Stock |
|
10MG | 51 | In Stock |
|
25MG | 79 | In Stock |
|
50MG | 133 | In Stock |
|
100MG | 177 | In Stock |
|
200MG | 259 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNavitoclax
-
NoteResearch use only, not for human use.
-
Brief DescriptionNavitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
-
DescriptionNavitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w; binds more weakly to Mcl-1 and A1 (Ki>350 nM); disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines (EC50<1 uM); induces complete tumor regressions in xenograft models of NSCLA and ALL.Blood Cancer Phase 2 Clinical
-
SynonymsABT-263;ABT 263;ABT263
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2;Bcl-w;Bcl-xL
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number923564-51-6
-
Formula Weight974.61
-
Molecular FormulaC47H55ClF3N5O6S3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
-
Chemical NameBenzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8.
2. Shoemaker AR, et al. Clin Cancer Res. 2008 Jun 1;14(11):3268-77.
3. Ackler S, et al. Mol Cancer Ther. 2008 Oct;7(10):3265-74.
4. Shah OJ, et al. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9.
2. Shoemaker AR, et al. Clin Cancer Res. 2008 Jun 1;14(11):3268-77.
3. Ackler S, et al. Mol Cancer Ther. 2008 Oct;7(10):3265-74.
4. Shah OJ, et al. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9.
molnova catalog
related products
-
Orobol
Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.
-
(-) BI97D6
(-) BI97D6 (BI112D1) is a potent, pan-active inhibitor of Bcl-2 family proteins with IC50 of 76, 31, 25, and 122 nM for Bcl-xL, Bcl-2, Mcl-1, and Bfl-1, respectively.
-
MIK665
MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.